Investigators pooled data from 4 trials to evaluate risk for recurrence in patients with intermediate risk non-muscle-invasive bladder cancer.

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

USA: A new systematic review published in the Cochrane Database of Systematic Reviews suggests that blue light-enhanced ...

New Delhi: Bladder cancer remains one of the most common urological cancers, yet early detection and monitoring of recurrence continue to challenge clinicians. New research now points to measurable ...

Analysis of Tumor Microenvironmental Features Between Primary and Synchronous Liver Metastases From Patients With Colorectal Cancers Using a Deep Learning Algorithm We present an automated tumor risk ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced muscle-invasive bladder cancer had lower risk for local recurrence with adjuvant ...

Frank Garred, 77, completed Inlexzo treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG. Frank Garred, a 77-year-old retiree from Denver, ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Surgery for advanced bladder cancer includes transurethral resection of the bladder tumor (TURBT) to remove tumors and cystectomy to remove all or part of the bladder, with the choice depending on the ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI ® (durvalumab) to BCG induction and maintenance ...